FDA Ex-U.S. Trial Filings Will Need “Explicit” Good Clinical Practice Info
FDA is moving toward requiring more "explicit" information on good clinical practice procedures for non-U.S. trials, Senior Advisor for Clinical Science David Lepay, MD/PhD, said at the Drug Information Association EuroMeeting in Prague March 13
You may also be interested in...
Sponsors should be responsible for oversight of adverse event safety data review to reduce institutional review board burden, Lilly Project Leader Vish Watkins says
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011